BB Biotech AG

Swiss Stock Exchange BION.SW

BB Biotech AG Price to Book Ratio (P/B) on January 14, 2025

BB Biotech AG Price to Book Ratio (P/B) is NA on January 14, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

BB Biotech AG 52-week high Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
BB Biotech AG 52-week low Price to Book Ratio (P/B) is NA on January 14, 2025, which is NA below the current Price to Book Ratio (P/B).
BB Biotech AG average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Swiss Stock Exchange: BION.SW

BB Biotech AG

CEO	Dr. Daniel Koller Ph.D.
IPO Date	Jan. 4, 2000
Location	Switzerland
Headquarters	Seestrasse 16
Employees	10
Sector	Health Care
Industries Biotechnology Hedge Funds Private Equity

Description

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Key trends

Past 5 years